MammaPrint laboratory service from Agendia BV is a FDA-cleared DNA microarray-based, in vitro diagnostic multivariate index assay (IVDMIA). MammaPrint measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint test measures the level of expression of each of these genes in a sample of a surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low-risk or high-risk for spread of the cancer to another site.
This article was published in Drug Discovery & Development magazine: Vol. 11, No. 6, June, 2008, pp. 33.
Filed Under: Genomics/Proteomics
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
